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This review provides a short history of the development of robotic systems in Clinical Chemistry and discusses the early expectations for these systems. The systems currently available are discussed and every attempt has been made to keep this section up-to-date, but this is a constantly changing field. Much of the review is taken up looking at the impact resulting from the introduction of robotic systems in the laboratory and whether they have met the expectations of the laboratory. It is difficult to get hard data since laboratories are most concerned with getting their instrumentation up and running and there is little time, or thought given, to pre-and post-introduction studies. Therefore, the literature is sparse but much of the data for the UK has come from a Medicines and Healthcare products Regulatory Agency (MHRA) review of pre-analytical systems. Finally thought has been given to future developments and their possible impact on the functioning of the laboratory. Ann Clin Biochem 2007; 44: [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] We have been familiar with automation of methods for many years where, after centrifugation and aliquoting, the only manual steps are to place the sample on the instrument and take it o¡ again. In such a process, the sample is static in that once placed in a sample holder it remains there. With improved computerization and engineering plus micro-electronics, instruments are now able to pick up samples and place them in a new position for additional processing --robotics. Using these de¢nitions, a single analyser represents an automated system and pre-analytical systems, that have a means to lift a sample from one processing unit to another, represent robotics. It is appreciated that some analysers do move samples but usually as a rack of samples before sampling. Nomenclature is even more confused in that the term 'Total Laboratory Automation or TLA' is used to describe a system that employs preanalytical, and possibly post-analytical robotics, with automated analysers. In this paper TLA will be used to describe such a system, otherwise robotics refers to pre-analytical and post-analytical systems.
Markin and Whalen 1 stated at the beginning of their paper on laboratory automation in 2000, 'laboratory automation is in its infancy'. Even at that stage large companies, such as Beckman Coulter and Roche Diagnostics, had spent a great deal of time and money on the development of robotics and they together with others are now well established globally. The introduction of robotics by other companies has been much slower and may be viewed as a relatively recent event and the amount of information on the reliability and e⁄ciency of such systems is limited.
History
In the mid-1980s there was little automation in pathology laboratories outside of chemistry analysers and certainly no robotics. Experience with early, automated pipetting systems was not encouraging, and there was a reluctance to adopt these early instruments. Gradually pipetting systems like those of Kemble Ltd 2 and Tecan (UK) Ltd were introduced into the routine laboratory along with semiautomated immunoassay systems like the Amerlite immunoassay system. 3 These pipetting stations cannot be described as true robotics since the sample remains still, and it is the pipetting arm that moves. Fully automated immunoassay analysers soon followed 4--7 and were an important addition as the workload of immunoassays continued to increase and new clinically important immunoassays were introduced. Automated systems removed tedious manual pipetting and, with further development, gave improved precision and faster assays, in many cases with smaller volumes of serum or plasma.
Three factors continued the pressure for further development. These were:
(a) a continuing increase in workload r 2007 The Association for Clinical Biochemistry (b) a need to reduce expenditure (hence working with a smaller workforce) (c) di⁄culties in recruitment of technical sta¡.
It was anticipated that automation would allow laboratories to manage the increased work with less skilled (and naturally lower paid) sta¡. The age of the push button laboratory had arrived --certainly in the minds of managers and government.
The possibility of automating all the steps from centrifugation through to sample analysis using robotics had been demonstrated by Dr M Sasaki 8 in Japan in 1984. This was a home-built system that had conveyer belts for sample transport. During the 1990s, a number of commercial systems, providing TLA, were installed in Japan and a few in the US. These were large expensive systems requiring large laboratory areas unavailable to the smaller UK laboratories. A solution to this problem was the introduction of pre-analytical robotic systems which carried out centrifugation, decapping, aliquoting and sorting. These enabled the manual repetitive steps to be automated without the need to be linked to an analyser. The advantages suggested for these systems included:
(a) the elimination of a signi¢cant number of errors resulting from manual procedures (b) a saving in the number of sta¡ (c) a levelling out of work £ow (d) a shorter and more predictable turnaround time (TAT) of results.
Such predictions were based on very limited or early theoretical information, and models used to provide data were often simplistic and na|« ve. The complexity of hospital laboratories with di¡erent sizes and work patterns was not fully considered. Markin and Whalen 1 suggested that 10--25 automated laboratory systems from di¡erent manufacturers, operated and studied over two years, would be required to generate meaningful statistical data on the optimum design and bene¢ts of robotics and automation.
Information and suggestions presented in this review may be site-speci¢c and not applicable to a wide range of hospitals. However, it is hoped that they may raise issues that will help laboratories in their future planning for the possible introduction and implementation of TLA. Many of the published reports come from the US and although size, approach, ¢nancing and pay back may be rather di¡erent from this country, there are some principles that are generally applicable. To give this review a non-US approach, data obtained from the Medicines and Healthcare products RegulatoryAgency (MHRA) evaluation 9 of pre-analytical systems in the UKwill be used to give an overview of the situation and experience in the UK and Europe. This review presents laboratory experience of introducing robotic systems and is not a purchasing guide or a Which? style report. Table 1 lists the systems that were evaluated in the MHRA report and the modules that were available from each company. However, the diagnostics industry is continually changing with new modi¢cations to instruments and take-overs. Recently, Ortho Diagnostics have introduced a robotic system developed by Thermo Electron Corporation. The sample tube carrier of this system incorporates a microchip for sample tracking, a design originally developed by CLIDS Oy, Finland. Other companies have introduced automated systems that either link two similar analysers together (DPC SMS) or a chemistry and immunoassay system (Olympus AU-Connector). Even more recently, Abbott Diagnostics have added a refrigerated archive/retrieval system to their total automation system. Just over 15,300 sample tubes can be stored in the present unit although there are plans to introduce units with even greater capacity. With the recent purchase of both DPC and Bayer by Siemens AG, we may see more signi¢cant changes to instrument availability in the near future.
Current systems available
It is not essential to have every module that a manufacturer o¡ers. For example, the Beckman Power Processor has a recapper module, but this was not ¢tted to the system at St Thomas' Hospital. Where a preanalytical system is linked to analysers, a recapper is useful for preparing samples for storage. In some cases, an automation system may be available by linking an analyser with another manufacturer's robotic system. This is the approach being adopted by Tosoh Corporation. The MHRA report gives a short account of the TC Automation, Thermo Electron Corporation, Finland, pre-analytical system at the Maggiore Hospital in Milan as no system was installed in the UK. It is reported that the analysers of several manufacturers may be linked to the system and is now part of the TLA system from Ortho Clinical Diagnostics. An automated pre-analytical system is also available from Sarstedt Ltd. No details were available for the MHRA report but it is reported that a series of platforms are available from the company for decapping only or decapping and sorting S-Monovette blood collection tubes only. 10 
Proposed advantages of robotic systems
A number of bene¢ts were proposed for the introduction of robotic systems in the laboratory. These were:
(a) sta¡ savings (b) reduction of errors (c) improvement in TAT (d) a more predictable throughput of samples (e) a cost-e⁄cient system with a short payback time.
Have these bene¢ts been realized in those laboratories that have been using a system for more than one year?
Staff savings
Felder 11 stated that sta¡ could be cut by up to 50%. In a simulated study in his department it was calculated that 2.5 full-time equivalents (FTEs) could be saved. However, he does not state what workforce was used as a starting point in his model, and the study involved only a small workload of 530 samples a day. These data were also used to calculate payback time, but this in turn would depend on the grade of sta¡ lost. This study used the Beckman Coulter IDS pre-analytical system with stand-alone Vitros chemistry analysers. More savings were expected if the analysers were linked to the robotic system.
Seaberg et al. 12 introduced TLA from Roche Diagnostics into their laboratory in 1999. This incorporated chemistry, haematology and coagulation. The company guaranteed that no more than 17.7 FTEs would be required to run 3775 specimens over 24 h. The authors reported that they employed nine FTEs to process 2000 specimens. They anticipated sta¡ savings of $2.7 million when fully implemented. They did not say what their workforce was before implementation of TLA. Holman et al. 13 reported on the introduction of theTecan Genesis FE500 automated pre-analytical system. Before the introduction of this stand-alone instrument,12 sta¡ were employed for the manual processing of 2000 specimens per day. After the introduction of the processor, only eight sta¡ were required. The MHRA evaluation of pre-analytical robotic systems 9 was not able to determine savings in sta¡ members although all sites involved expected to reduce sta¡ requirements. The estimated increase in sta¡ requirements, if these sites reverted to manual sample processing, was between two and four medical laboratory assistants (MLAs). In summary, the introduction of a robotic system does lead to fewer sta¡ required for processing routine samples. The cost savings depend on the level of sta¡ removed, and it is interesting that the UK laboratories considered that only MLA sta¡ were required for additional manual processing. Therefore, cost savings would be modest and payback time long. It seems reasonable to suggest that in the UK, robotics will release sta¡ to work either in other areas of the expanding laboratory or on developmental work.
Reduction of errors
Manual operations are generally perceived to be a source of errors. One of the ¢rst studies of human error in clinical practice was carried out in 1984 when 30,121 medical notes in the State of New York were reviewed for medical errors. ' Adverse events' were recorded in 3.7%, of which 27.6% were due to negligence. 14, 15 No estimate was made of the percentage due to laboratory errors. Bissell 16 suggested 1--2% as the overall human error rate although this was not based on any laboratory data. He used this estimate to point out the potential for laboratory errors making a signi¢cant contribution to health system costs. Therefore, pre-analytical robotics can be expected to bring about a reduction in those errors that occur during centrifugation, aliquoting and labelling of aliquots. Markin and Whalen 1 examined errors before and after installing a LAB-Interlink automation system at the Aultman Hospital in Canton, Ohio, USA. Before automation, the number of errors in chemistry and haematology ranged from about 22 to 52, but after automation, fell to between 4 and 11. They do not say what percentage these represented of the total workload nor what the errors were. In 2000, Swaminathan and Wheeler 17 examined the number and types of error that resulted in a result not reaching the requesting doctor. A total of 1759 requests were examined. Less than 0.2% of errors were due to breakages, mislabelling and mislaid samples; errors that would be addressed by pre-analytical robotics. The total error rate was 4.3% with the majority of errors occurring at data entry. Even a 0.2% error rate represents 1000 patient requests a year for a workload of 0.5 million requests a year. This represents much time and inconvenience for sta¡, clinicians and patients in obtaining another sample as well as the potential of a wrong result being sent out and acted upon. Holman et al. 13 also looked at errors in the routine setting and found an error rate of o 1%. Figure 1 derived from their data shows that the error rate fell dramatically after the installation of the Genesis FE500 automated sample processor. In summary, robotic systems lead to a reduction of manual handling errors. However, the errors that are eliminated represent a small proportion of pre-analytical errors.
Turnaround time and sample delivery
Markin and Whalen 1 also examined TAT before and after the introduction of automation. TAT for urea measurement fell from just over 60 to 40 min. Delays in sample throughput frequently occur at times of high workload. Centrifugation is a well-recognized bottleneck, and it is important that a careful calculation is carried out of the sample throughput of the centrifuge.
This appeared to be an issue at two sites participating in the MHRA evaluation. At one site using the Roche modular pre-analytic (MPA) system, the supplier initially provided a single centrifuge. Figure 2 shows that at several times during the day, it took 2.5--3 h before a sodium result was available; at other times it took about 1h. The introduction of a second centrifuge dramatically smoothed out the turnaround time and it became more predictable. Only over one short period did the TAT exceed 2 h and for most of the day,TAT was approximately 1h from entry into the laboratory information system (LIS) to the result becoming available. At a second site using the Genesis FE500, the laboratory had to resort to manual processing of samples because the processor was unable to handle the workload during peak times. In this latter case, additional sta¡ would be required in the afternoon so sta¡ savings would be less. TAT is in£uenced by the workload and the number of sta¡ available to carry out manual processing. At a third site, manual processing was very e⁄cient ( Figure 3 ) and only in the early morning did TAT exceed 1.5 h. Introduction of a Roche MPA system into the laboratory reduced the TAT in the morning but not at other times during the day when manual processing had a shorter TAT. The bene¢t to this laboratory may well have been in a reduction in the number of sta¡ used for pre-analytical work but this was not assessed. Figure 3 A comparison of throughput time before and after the introduction of a Roche MPA pre-analytical system (from Piggott et al. 9 with permission)
The above information for systems in routine use in this country and the US indicates that the introduction of an automated pre-analytical processor allows reduction in sta¡ in the pre-analytical area, leads to a reduction in handling errors and smoothes out work-£ow making TAT more predictable. It may not lead to an improvement in TAT at all times during the day as this depends on the e⁄ciency of the previous manual system. If the routine analysers are linked to the pre-analytical robotics, further sta¡ savings may be predicted with shorter TAT as there is immediate delivery of sample to the analyser.
Cost-effectiveness
Because of the di¡erent ways that health services are ¢nanced in di¡erent countries, measuring cost bene¢ts will di¡er. In the US, the focus is on the length of time it takes to pay back the cost of a system. In the UK, calculations are based more on managing an increasing workload and additional tests without increasing the workforce. At various meetings over recent years, payback times have ranged from three years to 10 years. The length of time di¡ers depending on the extent of the automation, the size of the laboratory and its workforce, the parameters included in the calculation and, if sta¡ numbers are reduced, the grade of sta¡. Markin and Whalen 1 reported a reduction of 35 FTEs, including four managers (bigger than the total technical workforce of many UK laboratories!) equivalent to a saving of $1.2 million over two years. This was achieved by a major consolidation of work, introduction of a tube system along with the robotics, and a change of work pattern.
In the UK, cost e¡ectiveness must be calculated through cost per test based on the total laboratory operating costs and the laboratory workforce. Even this simple approach is complex, as many will have experienced through the various benchmarking exercises. 18, 19 Measurands must be standardized. For example, the number of samples coming into a laboratory will depend on the type and size of the hospital, the number of services/general practitioner clinics it serves outside of the Trust and whether it provides a signi¢cant supraregional service. However, from the replies of those participating in the MHRA survey 9 fewer sta¡ were required in the pre-analytical area with the introduction of robotics and greater savings could be achieved if this was combined with consolidation of services.
Installation time
The longest process in obtaining a robotic system in the UK is the procurement process. Centres reported that the time from placing the tender advert to placing the order took between 11 months and 20 months. Having placed the advert, there may be a delay waiting for an instrument to become available or for the robotic system to be built, assembled and tested before installation. Personal experience is that it may take up to six months before a system can be installed although analysers might be delivered much sooner. Pre-analytical modular systems are available sooner, although the software will need modifying for the sample and sorting needs of the customer. Delivery and implementation of a system can be surprisingly short and depends on whether a system has been installed before. At St Thomas' Hospital, it took over 12 months before the ¢rst pre-analytical system was fully implemented but only three weeks when this was replaced by the Beckman Power Processor. The installation period will also depend on the complexity of the system, but as companies gain more experience of installation at different sites, full implementation should be achieved after only four weeks.
Laboratories should anticipate disruption and slower TAT when the robotic system of TLA is installed since there must be testing of the analyser link to the track system. This should be of only a few days'duration, but as it may a¡ect analysis of urgent samples, clinicians should be warned. Usually more than one analyser is installed in a laboratory, and it is possible to test links with one analyser while the other is used to process the routine samples o¥ine. This in itself assumes one analyser is able to provide all the tests required, an infrequent occurrence these days. The process of assessing the needs for robotics, choosing equipment and the purchasing process is a large topic in itself and will be the subject of a separate review. Table 2 lists the limitations and potential errors that could be encountered with a robotic system. It should be appreciated that a signi¢cant amount of work may not be processed by the pre-analytical system. Some systems, e.g. Beckman Power Processor, can accommodate only one size of tube. Therefore, if a di¡erent size of tube is used for some tests, e.g. glucose and paediatric, these samples will have to be processed manually and placed on the analysers as STAT samples if the analyser is linked to a track system. This was the experience at St Thomas' Hospital and caused a lot of manual sample handling and meant the robot was not being used e⁄ciently. It was decided to reduce this work by using the larger tube size for glucose as used for other routine testing. This meant that considerably more blood than necessary was taken from the patient, an issue raised by Hicks. 20 Paediatric and small volumes still had to be manually prepared, and this is one reason why reduction in sta¡ numbers is less than anticipated. It is not e⁄cient to handle urgent samples manually on most systems. A single sample can be added to a robotic system as a STAT sample, and on the Beckman Power Processor this would take only 12 min to process before being ready for the analysers. Manual centrifugation has many potential delays --a centrifuge may not be immediately available, centrifugation itself may be 10 min and the sample is seldom put on the analyser as soon as the centrifuge stops. This would not happen on a TLA system and processing time is likely to be quicker. A processing time similar to that of the Beckman was found for the Genesis FE500. 10 The system has to be of a su⁄cient size to cope with the workload at all times. The system should also have redundancy built in to manage the work during downtimes. This has been discussed before, and it has been demonstrated that inadequate centrifuge capacity will lead to backlogs. The inability to purchase an instrument of a su⁄cient size leads to self-imposed limitations, and the full bene¢t of the robotic system will not be fully realized. This can be very frustrating for sta¡ who will see the potential of the system but are unable to utilize it.
Limitations and potential errors
Equally the more manual processes that still have to be carried out reduce the impact of a robotic system. Some systems do not have an aliquoter (Table 1) , and this process, therefore, has to be performed manually leading to potential errors. Others do not have a centrifuge. Therefore, some systems have inherent operating limitations. Such limitations have to be set against the budget available, the space limitations, required savings either from a reduction in sta¡ numbers or reagent savings and the ability to make further savings from consolidation. It is important that sta¡ are fully involved and informed so that they can fully appreciate the limitations and are more prepared to live with them.
Most potential errors listed in Table 2 are only theoretical. A robotic system that is operating well has minimum errors and downtime. Rejected samples are generally due to poor barcode labels and short samples. These have to be handled manually.
The most signi¢cant problem that has been identi¢ed is evaporation. Evaporation can occur through delays after decapping and before reaching the analysers or post analysis. The air-conditioning and temperature of the laboratory can have a marked e¡ect on evaporation. The Royal Free Hospital 9 experienced evaporation due to air-conditioning problems, and Walsgrave Hospital 9 had to resort to chilling aliquot cups if analysers were not functional. If tubes cannot be analysed due to analyser failure, then they will need to be recapped or placed in a refrigerator until they can be analysed. They may have to be loaded manually onto the analysers once operational to reduce further delays. This in itself will cause delays and require additional sta¡ time.
Contamination between di¡erent samples was a major concern of the virologists at St Thomas' Hospital, whose samples are aliquoted on the pre-analytical system. Contamination of equipment and between samples is most likely at the aliquoting step. This can be caused by drips resulting from poorly ¢tting aliquot tips or the movement of tubing supplying the aliquoting arms. Only where a tray tracks underneath the pipette tip, such as on the Beckman Coulter and Roche systems, or in other systems where the tip never passes over another tube is contamination of another sample avoided. A new pipette tip or £ushing pipetting lines may not address the potential problems above, and contamination should always be investigated. At St Thomas' Hospital a dye system was used regularly as a quality control procedure to investigate cross-contamination within the system.
Pre-analytical systems do not have sample integrity testing (examining for haemolysis, lipaemia and icterus). Although chemistry analysers have integrity checking, immunoassay analysers do not, and it is not cost e¡ective in time or reagent for all immunoassay samples to pass through a chemistry analyser, although most samples probably will pass through a chemistry analyser, since thyroid function tests are a major part of ordered pro¢les. However, MHRA evaluations have shown that the integrity checking of some chemistry analysers is not totally reliable. 21, 22 Sta¡ must be very vigilant and challenge any unusual results as well as check immunoassay results on samples rejected on the chemistry analyser.
Meeting expectations
It has been predicted that pre-analytical robotics would improve TAT, remove backlogs during peak times and reduce sta¡ requirements and hence save money. It would appear that these expectations have been met much of the time, but not in all cases.
The most e⁄cient use of pre-analytical systems is to have them linked directly to analysers and run them for a least 14 h a day but preferably for 24 h. At St Thomas' Hospital, the Beckman robotic system is run from 0800 h to no later than 2000 h. It was felt that this was under-use of the system. Although the Power Processor can be linked to the LX20 chemistry analyser, this was not achieved for any length of time at St Thomas'. Frequent analyser problems resulted in large backlogs indicating that high analyser reliability, and additional analysers are required to cope with periods of analyser downtime. The two LX20 analysers are heavily used at St Thomas'and are insu⁄cient for operating a fully integrated robotic system. When one instrument breaks down, a backlog of samples quickly builds up. Therefore, there should be su⁄cient duplication of analysers so that should an analyser stop working, the TAT is not compromised. Today an entire menu of tests o¡ered by the laboratory can no longer be accommodated on one instrument as it exceeds the capacity of a single analyser. A common practice is to have the largest requested analyses on both instruments and to have those assays requested less frequently split between the two instruments or run on only one instrument. A breakdown of one instrument means that some tests cannot be performed, thus increasing TAT of these tests. Two analysers, therefore, are inadequate for the busy laboratory. One approach to overcome this problem is to have a pre-analytical system supplying two independent analytical channels. Failure of one channel allows samples to be re-directed to the other. At the Royal Free Hospital, three Roche P800 chemistry analysers are arranged in tandem. 9 Therefore, a certain amount of redundancy has to be built into the system to overcome or reduce backlogs to a minimum during downtimes and system failures.
It is wise to plan for the requirements of the next three to ¢ve years when choosing TLA. Pathology modernization 23 is likely to lead to greater centralization of less urgent tests on one site. In a cluster, for example, one site may do all the endocrinology apart from thyroid function tests. This is more likely to be centred on the site with TLA. Also more and more tests are becoming available on the large automated analysers, and the capacity of analysers will soon be reached and additional analysers required. If such scenarios appear likely, TLA should, whenever possible, have the capacity to accept a further immunoassay analyser and possibly an additional chemistry analyser as well.
More space should be needed if haematology analysers are to be accommodated in the future. The Bayer system at Frimley Park Hospital has two ADMA 120 haematology analysers and two bioMerieux MDA 180 coagulation analysers as well as two ADVIA Centaurs and two ADVIA 1650 chemistry analysers. 9 
Future developments
Although companies will have a number of developments in the pipeline, there is nothing novel yet being discussed. New developments within robotics and laboratory automation currently discussed are of additions to current systems (e.g. Abbott Diagnostics are developing an aliquoter unit) and amalgamations between companies, e.g. the purchase of DPC and Bayer by Siemens AG. Future developments may be outside the routine laboratory. There is a lot of e¡ort going into the development of point-of-care testing, particularly, with an eye on moving more into the community. 24, 25 Many laboratories are developing tandem mass spectrometry methods 26, 27 but the equipment and the companies which provide them are not yet at a level where they can meet the needs of the routine laboratory. Also we have yet to see polymerase chain reaction (PCR) and microarray technology making a signi¢cant impact in the routine clinical biochemistry laboratory. No doubt PCR and microarray equipment for routine testing is just over the horizon. Therefore, for the routine laboratory, the trend to laboratory automation will continue with few new developments in this area from the companies. Purchase of this equipment should be part of a 10-year plan that should consider consolidation of pathology disciplines as well as similar methodologies. The hardest part will be persuading hospital managers to invest in such an exercise.
The above account gives an overview of the experiences of laboratories that have introduced robotics and automation, and raises a number of issues that laboratories should consider when purchasing a new system. It was not the intention of this review to give an outline for purchasing new instrumentation and this will be dealt with in another paper. However, Table 3 summarizes points that laboratories should take note of during the planning process.
Summary
Those laboratories with the workload and su⁄cient work area are moving towards TLA. However, such technology is still in its infancy and several sites in the UK have found that installation of the ¢rst system is a protracted process. Teething problems have been experienced, and it has sometimes taken 12 months before the system is fully operational. This may mean 12 months of frustration, lengthening TAT and stress for the sta¡. If TLA that encompasses more than one discipline is introduced, then thought will have to be given to cross training of sta¡.
It makes sense to utilize the e⁄ciency of robotics for as much of the working day as possible. Theoretically robotics are available 24 h a day and being able to place a sample directly onto a robotics system that centrifuges, aliquots, analyses and issues results should make the life of on-call sta¡ much easier. This raises the issue of whether it is more e⁄cient to run all samples throughout the night. If the number of sta¡ can be reduced during the day, then more sta¡ could be transferred to the night. If all samples coming in at the end of the day and during the night are analysed immediately, then no samples will be waiting for analysis in the morning. Hence TAT will be improved, backlogs reduced and the work£ow more even. An on-call night service with additional sta¡ will increase costs signi¢cantly and so TLA is best suited to a shift system or extended working day.
Whether pre-analytical modules have the same impact is unknown although it is reported that sta¡ using the Genesis FE500 ¢nd it simpler to use this instrument to do the sample preparation. However, unless sta¡ are diligent in placing samples directly onto analysers, as soon as they are available, additional delays can be expected. As already mentioned one centre bought a single Genesis FE500, but found it inadequate during their busy periods. Such an arrangement, i.e. part robotic, part manual does not seem rational and does not utilize the full impact of robotics.
However, whether a laboratory pursues TLA or a modular solution, careful planning is essential. On-site visits and discussions with existing users are essential to ¢nd out about all the limitations of the system, its reliability and the support from the company. An increase of 5--10% per year in workload should be anticipated in any calculations of workload. It is also important to ¢nd out from companies about future developments and the anticipated timescale. Once introduced, you are going to have to live with your system and your sta¡ (if they stay) for at least ¢ve years!
